Scarica l'app Stockscreener
0.7945
2.40%
-0.0195
Dopo l'orario di chiusura:
.81
0.0155
+1.95%
Precedente Chiudi:
$0.814
Aprire:
$0.83
Volume 24 ore:
241.25K
Relative Volume:
0.33
Capitalizzazione di mercato:
$99.47M
Reddito:
$140.46M
Utile/perdita netta:
$-146.34M
Rapporto P/E:
-0.6019
EPS:
-1.32
Flusso di cassa netto:
$-117.73M
1 W Prestazione:
-13.81%
1M Prestazione:
-8.69%
6M Prestazione:
-30.91%
1 anno Prestazione:
+1.86%
Intervallo 1D:
$0.7809
$0.859
Intervallo di 1 settimana:
$0.7809
$0.9495
Portata 52W:
$0.6174
$1.95
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Nome
Karyopharm Therapeutics Inc
Settore
Industria
Telefono
617-658-0600
Indirizzo
85 WELLS AVENUE, NEWTON, MA
Confronta KPTI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| KPTI | 0.7945 | 99.47M | 140.46M | -146.34M | -117.73M | -1.32 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-01-19 | Iniziato | Piper Sandler | Overweight |
| 2022-11-04 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-09 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-11-19 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-08-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-08-06 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-08-06 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-07-02 | Iniziato | Morgan Stanley | Overweight |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-17 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-07-23 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-07-05 | Reiterato | H.C. Wainwright | Buy |
| 2019-07-05 | Reiterato | Robert W. Baird | Outperform |
| 2019-03-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-02-28 | Reiterato | BofA/Merrill | Underperform |
| 2019-02-27 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2019-01-03 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2018-12-03 | Iniziato | B. Riley FBR | Buy |
| 2018-11-09 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2018-05-24 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-04-02 | Ripresa | Leerink Partners | Outperform |
| 2017-11-15 | Ripresa | H.C. Wainwright | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
| 2016-09-08 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-30 | Aggiornamento | Jefferies | Hold → Buy |
| 2016-08-18 | Iniziato | H.C. Wainwright | Buy |
| 2016-06-28 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Karyopharm Therapeutics Inc Borsa (KPTI) Ultime notizie
Karyopharm to Present New Selinexor Clinical Data at ASH 2024 Annual Meeting | KPTI Stock News - StockTitan
Avidity Partners Management LP's Strategic Acquisition of Karyop - GuruFocus.com
Karyopharm Therapeutics' SWOT analysis: stock outlook amid pipeline progress By Investing.com - Investing.com Nigeria
Karyopharm Therapeutics' SWOT analysis: stock outlook amid pipeline progress - Investing.com India
Karyopharm Therapeutics (NASDAQ:KPTI) Stock Rating Upgraded by StockNews.com - MarketBeat
GSA Capital Partners LLP Purchases 792,283 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - MarketBeat
Leerink Partnrs Issues Optimistic Forecast for KPTI Earnings - MarketBeat
What is HC Wainwright's Estimate for KPTI FY2024 Earnings? - MarketBeat
Karyopharm Therapeutics Falls To US$0.88, But Insiders Sold At Lower Price - Simply Wall St
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - Yahoo Finance
Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Expected to Rise, Piper Sandler Analyst Says - Defense World
Karyopharm Therapeutics Reports Q3 2024 Financial Results and Corporate Progress - Defense World
Karyopharm Therapeutics Inc (KPTI) Is Worth Accumulating At Current Levels - Stocks Register
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q3 2024 Earnings Call Transcript - Insider Monkey
Karyopharm stock price target raised, overweight on revenue beat - Investing.com India
Karyopharm therapeutics CEO Richard Paulson sells $3,346 in stock - Investing.com
Karyopharm therapeutics CEO Richard Paulson sells $3,346 in stock By Investing.com - Investing.com Canada
Karyopharm stock price target raised, overweight on revenue beat By Investing.com - Investing.com Australia
Earnings call: Karyopharm Therapeutics reports on clinical and financial progress - Investing.com Nigeria
Piper Sandler Boosts Karyopharm Therapeutics (NASDAQ:KPTI) Price Target to $5.00 - MarketBeat
Karyopharm price target raised to $5 from $4 at Piper Sandler - TipRanks
Karyopharm Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Karyopharm Therapeutics Inc (KPTI) Q3 2024 Earnings Call Highlig - GuruFocus.com
Karyopharm Therapeutics' SWOT analysis: oncology firm's stock faces pivotal year - Investing.com Australia
Karyopharm Therapeutics Inc (KPTI) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ... - Yahoo Finance
Karyopharm Therapeutics Inc. Reports Q3 2024 Earnings - TipRanks
Karyopharm Therapeutics Q3 2024 Earnings Preview - MSN
Karyopharm Therapeutics (KPTI) Q3 2024 Earnings Call Transcript - AOL
Karyopharm Therapeutics: Q3 Earnings Snapshot - San Francisco Chronicle
Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Karyopharm Therapeutics Inc (KPTI) Q3 2024 Earnings: EPS Loss of - GuruFocus.com
Karyopharm Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress - PR Newswire
Karyopharm Therapeutics Inc (KPTI) Q3 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus.com
KPTIKaryopharm Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
Karyopharm Therapeutics (KPTI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release - MSN
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - WV News
Karyopharm Therapeutics (KPTI) to Release Quarterly Earnings on Tuesday - MarketBeat
Karyopharm Therapeutics' (KPTI) Buy Rating Reiterated at HC Wainwright - MarketBeat
Karyopharm updates SENTRY trial endpoints, eyes 2025 data - Investing.com India
Karyopharm updates SENTRY trial endpoints, eyes 2025 data By Investing.com - Investing.com Canada
Karyopharm gains after changes to late-stage trial - MSN
Karyopharm stock gains as late-stage trial changes (KPTI:NASDAQ) - Seeking Alpha
Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024 - StockTitan
Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis - Kilgore News Herald
Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024 - Investor Relations | Karyopharm Therapeutics
Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Passes Below 200 Day Moving AverageHere's What Happened - MarketBeat
Karyopharm Therapeutics Inc Azioni (KPTI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):